Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AJANTA PHARMA Mar-19 |
TEVA PHARMA Dec-13 |
AJANTA PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,422 | 3,088 | - | |
Low | Rs | 898 | 2,683 | - | |
Sales per share (Unadj.) | Rs | 233.5 | 1,772.2 | - | |
Earnings per share (Unadj.) | Rs | 44.0 | 110.7 | - | |
Cash flow per share (Unadj.) | Rs | 52.2 | 254.0 | - | |
Dividends per share (Unadj.) | Rs | 9.00 | 96.91 | - | |
Dividend yield (eoy) | % | 0.8 | 3.4 | 23.1% | |
Book value per share (Unadj.) | Rs | 255.1 | 1,968.6 | - | |
Shares outstanding (eoy) | m | 88.02 | 848.00 | - | |
Bonus/Rights/Conversions | BB | - | - | ||
Price / Sales ratio | x | 5.0 | 1.6 | 305.1% | |
Avg P/E ratio | x | 26.4 | 26.1 | 101.2% | |
P/CF ratio (eoy) | x | 22.2 | 11.4 | 195.7% | |
Price / Book Value ratio | x | 4.5 | 1.5 | 310.2% | |
Dividend payout | % | 20.5 | 87.5 | 23.4% | |
Avg Mkt Cap | Rs m | 102,081 | 2,446,667 | 4.2% | |
No. of employees | `000 | 6.8 | 44.9 | 15.1% | |
Total wages/salary | Rs m | 4,307 | 0 | - | |
Avg. sales/employee | Rs Th | 3,022.6 | 33,437.1 | 9.0% | |
Avg. wages/employee | Rs Th | 633.4 | 0 | - | |
Avg. net profit/employee | Rs Th | 569.1 | 2,088.8 | 27.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,554 | 1,502,830 | 1.4% | |
Other income | Rs m | 211 | 0 | - | |
Total revenues | Rs m | 20,765 | 1,502,830 | 1.4% | |
Gross profit | Rs m | 5,664 | 411,551 | 1.4% | |
Depreciation | Rs m | 721 | 121,475 | 0.6% | |
Interest | Rs m | 12 | 29,518 | 0.0% | |
Profit before tax | Rs m | 5,143 | 260,558 | 2.0% | |
Minority Interest | Rs m | 0 | 1,184 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -171,042 | 0.0% | |
Tax | Rs m | 1,273 | -3,181 | -40.0% | |
Profit after tax | Rs m | 3,870 | 93,881 | 4.1% | |
Gross profit margin | % | 27.6 | 27.4 | 100.6% | |
Effective tax rate | % | 24.8 | -1.2 | -2,027.5% | |
Net profit margin | % | 18.8 | 6.2 | 301.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,812 | 1,015,006 | 1.2% | |
Current liabilities | Rs m | 3,776 | 885,171 | 0.4% | |
Net working cap to sales | % | 39.1 | 8.6 | 452.5% | |
Current ratio | x | 3.1 | 1.1 | 272.8% | |
Inventory Days | Days | 77 | 91 | 85.2% | |
Debtors Days | Days | 82 | 96 | 85.1% | |
Net fixed assets | Rs m | 14,398 | 490,857 | 2.9% | |
Share capital | Rs m | 175 | 3,699 | 4.7% | |
Net worth | Rs m | 22,452 | 1,669,359 | 1.3% | |
Long term debt | Rs m | 7 | 768,430 | 0.0% | |
Total assets | Rs m | 26,962 | 3,434,448 | 0.8% | |
Interest coverage | x | 444.3 | 9.8 | 4,521.6% | |
Debt to equity ratio | x | 0 | 0.5 | 0.1% | |
Sales to assets ratio | x | 0.8 | 0.4 | 174.2% | |
Return on assets | % | 14.4 | 3.6 | 400.7% | |
Return on equity | % | 17.2 | 5.6 | 306.5% | |
Return on capital | % | 23.0 | 4.9 | 465.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,748 | 239,473 | 1.6% | |
From Investments | Rs m | -2,228 | -84,855 | 2.6% | |
From Financial Activity | Rs m | -1,475 | -287,264 | 0.5% | |
Net Cashflow | Rs m | 45 | -132,646 | -0.0% |
Compare AJANTA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare AJANTA PHARMA With: NOVARTIS IPCA LABS DIVIS LABORATORIES LUPIN DR. REDDYS LAB
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More